EUVIMEDEUVIMED entdecken
Open Access

Tirzepatide alleviates non-alcoholic fatty liver disease by regulating lipid metabolism through activation of the AMPK/NF-κB signaling pathway

Pengfei Wu, Hao Xu, Yuqiao Zeng, Ao Shen, Cheng Zhang, Bing Wu, Xinyue Zhang, Han Zhang, Yiyu He, Likun Wang

American Journal of Translational Research · 2025 · 17 (12) · 9555-9565

DOI: 10.62347/snzk2023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Translational Research, 2025. Verfasst von Pengfei Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Medicine, Shandong Second Medical University Weifang 261053, Shandong, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a prevalent metabolic disorder with limited therapeutic options. Tirzepatide (TZP), a novel dual agonist, has shown promise in metabolic disease, but its effects and mechanisms in NAFLD remain unclear. METHODS: Human HepG2 cells were treated with palmitate (PA) to induce steatosis and then exposed to various concentrations of TZP. Mouse were treated with high-fat diet (HFD) to establish a NAFLD model in vivo, followed by TZP treatment. NAFLD-related indicators including cell viability, intracellular lipid accumulation, serum biochemical parameters, glucose homeostasis, inflammation, oxidative stress, and hepatic histopathology were evaluated. The AMP-activated protein kinase (AMPK)/nuclear factor κB (NF-κB) pathway and lipid metabolism-related protein were analyzed. RESULTS: TZP suppressed PA-induced lipid accumulation, triglyceride and total cholesterol content, cell apoptosis, while it enhanced cell viability in HepG2 cells. In HFD-induced NAFLD mice, TZP treatment markedly decreased liver weight, attenuated hepatic steatosis, ballooning, and necrosis, and abnormal lipid accumulation by inhibiting insulin resistance, inflammatory cytokines, oxidative stress, and hepatic fibrosis markers. Mechanistically, TZP modulated the AMPK/NF-κB pathway by increasing p-AMPK and decreasing p-NF-κB levels, leading to downregulation of lipogenic genes. CONCLUSION: TZP effectively improved hepatic steatosis, inflammation, oxidative stress, and fibrosis in experimental NAFLD models through the AMPK/NF-κB pathway.

Schlagwörter

Stichwörter der Autor:innen

AMPK/NF-κB pathwayTirzepatidelipid metabolismnon-alcoholic fatty liver disease

Autor:innen und Institutionen

  • School of Clinical Medicine, Shandong Second Medical University Weifang 261053, Shandong, China.
  • Infection Control Center, Linyi People's Hospital Linyi 276000, Shandong, China.
  • Department of Cardiovescular Disease, Renmin Hospital of Wuhan University Wuhan 430060, Hubei, China.

Zitieren

APA

Wu, P., Xu, H., Zeng, Y., Shen, A., Zhang, C., Wu, B., Zhang, X., Zhang, H., He, Y., & Wang, L. (2025). Tirzepatide alleviates non-alcoholic fatty liver disease by regulating lipid metabolism through activation of the AMPK/NF-κB signaling pathway. American Journal of Translational Research, 17(12), 9555-9565. https://doi.org/10.62347/snzk2023

Vancouver

Wu P, Xu H, Zeng Y, Shen A, Zhang C, Wu B, et al. Tirzepatide alleviates non-alcoholic fatty liver disease by regulating lipid metabolism through activation of the AMPK/NF-κB signaling pathway. American Journal of Translational Research. 2025;17(12):9555-9565. doi:10.62347/snzk2023

BibTeX
@article{Wu2025,
  author = {Wu, Pengfei and Xu, Hao and Zeng, Yuqiao and Shen, Ao and Zhang, Cheng and Wu, Bing and Zhang, Xinyue and Zhang, Han and He, Yiyu and Wang, Likun},
  title = {Tirzepatide alleviates non-alcoholic fatty liver disease by regulating lipid metabolism through activation of the AMPK/NF-κB signaling pathway},
  journal = {American Journal of Translational Research},
  year = {2025},
  volume = {17},
  number = {12},
  pages = {9555--9565},
  doi = {10.62347/snzk2023}
}
Kostenlos starten →